Pfizer (PFE) Receivables (2009 - 2026)

Pfizer (PFE) has 18 years of Receivables data on file, last reported at $12.6 billion in Q1 2026.

• Receivables for Q1 2026 came in at $12.6 billion, up 6.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.6 billion (up 6.25% YoY), and the FY2025 annual result was $11.9 billion, up 3.59% from the prior year.
• Receivables improved to $12.6 billion in Q1 2026 per PFE's latest filing, from $11.9 billion in the prior quarter.
• Over five years, Receivables peaked at $16.2 billion in Q4 2022 and troughed at $10.2 billion in Q3 2023.
• A 5-year average of $12.5 billion and a median of $11.9 billion in 2025 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables surged 39.98% in 2022, then plunged 33.68% in 2023.
• A 5-year view of Receivables shows it stood at $11.0 billion in 2022, then grew by 5.61% to $11.6 billion in 2023, then fell by 0.89% to $11.5 billion in 2024, then gained by 3.59% to $11.9 billion in 2025, then grew by 5.99% to $12.6 billion in 2026.
• Business Quant data shows PFE's Receivables at $12.6 billion in Q1 2026, $11.9 billion in Q4 2025, and $14.3 billion in Q3 2025.